Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Total Debt (2018 - 2025)

Historic Total Debt for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Q1 2025 value amounting to $15.0 million.

  • Arcturus Therapeutics Holdings' Total Debt changed N/A to $15.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $15.0 million, marking a year-over-year change of. This contributed to the annual value of $60.7 million for FY2022, which is 388.55% down from last year.
  • Arcturus Therapeutics Holdings' Total Debt amounted to $15.0 million in Q1 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Total Debt ranged from a high of $63.5 million in Q1 2022 and a low of $15.0 million during Q1 2025
  • For the 4-year period, Arcturus Therapeutics Holdings' Total Debt averaged around $52.8 million, with its median value being $61.0 million (2021).
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' Total Debt skyrocketed by 31806.56% in 2021 and then plummeted by 6652.16% in 2023.
  • Over the past 4 years, Arcturus Therapeutics Holdings' Total Debt (Quarter) stood at $63.1 million in 2021, then fell by 3.89% to $60.7 million in 2022, then tumbled by 67.03% to $20.0 million in 2023, then dropped by 25.0% to $15.0 million in 2025.
  • Its Total Debt stands at $15.0 million for Q1 2025, versus $20.0 million for Q3 2023 and $60.7 million for Q4 2022.